Skip to content
    UNH
    Earnings call· Jun 2026(Q2 FY26)

    UNITEDHEALTH GROUP Q2 FY26 earnings call UNH

    Jul 16, 2026 Source

    Executive summary

    UnitedHealth Group Q2 FY26 — Strong Performance Driven by Medicare and Optum, Commercial Pressures Persist

    UnitedHealth Group delivered a strong second quarter, exceeding expectations in Medicare and Optum segments, while commercial medical cost trends remained elevated. The company is actively leveraging AI and strategic investments to modernize healthcare experiences, improve operational efficiencies, and drive long-term growth, despite ongoing pressures in certain benefit areas. Management remains committed to its 13-16% long-term growth algorithm.

    Highlights

    5

    • Adjusted EPS grew 56.4% to $6.38 compared to $4.08 in the prior year.

    • Operating earnings grew 55% year-over-year to $8 billion.

    • Operating cash flows were approximately $11 billion, 1.9x net income.

    • Medicare Advantage enrollment decline now expected to be approximately $1.1 million, better than previously anticipated.

    • Patient experience in OptumHealth care delivery sites is up approximately 5% year-over-year, and patient access expanded by nearly 200,000 patient-facing hours.

    Concerns

    3

    • Commercial medical cost trends are stubbornly high, modestly above 11%, driven by the No Surprises Act IDR process and aggressive billing.

    • Medicaid margins are expected to remain pressured for 2026, within the negative 1% to negative 1.7% range, due to lagging reimbursement rates.

    • Commercial margin recovery trajectory is extended past 2027 due to persistent elevated trend.

    Guidance & targets

    13
    CategoryTargetConfidence
    Full year 2026 adjusted EPS
    $19.50 to $20.00
    high materiality
    High
    Full year 2026 UnitedHealthcare operating earnings
    at least $12 billion
    high materiality
    High
    Full year 2026 Optum Health operating earnings
    at least $2.2 billion
    high materiality
    High
    Full year 2026 medical care ratio
    88.1% plus or minus 25 basis points
    high materiality
    High
    Full year 2026 share repurchases
    at least $5 billion
    high materiality
    High
    Debt-to-capital ratio
    approximately 40%
    medium materiality
    High
    Medicare Advantage enrollment decline
    approximately $1.1 million
    high materiality
    High
    Medicare margins
    above 3%
    high materiality
    High
    Prior authorization volume reduction
    30%
    medium materiality
    High
    Prior authorization requirements for pediatric care reduction
    nearly 2/3
    medium materiality
    High
    OptumHealth AI-based ambient listening capabilities
    exceed 90%
    low materiality
    High
    Manufacturer rebates pass-through
    100%
    medium materiality
    High
    Prior authorization processing in real time
    80%
    medium materiality
    High

    Segment performance

    4
    SegmentRevenueYoYQoQMargin
    UnitedHealthcare
    Improved performance in Medicare businesses through benefit planning, design, care management, and network curation. Commercial benefits remain pressured by higher-than-expected cost trends.
    Medicare Advantage enrollment decline: approximately $1.1 millionMedicare margins: above 3%
    		————
    Optum Health
    Building momentum from recentering to integrated value-based care. Significant changes in operations are yielding tangible results in clinical care and operational experience. Margins expected to continue to steadily improve.
    10% reduction in hospitalization since late last year in Western and Southern regionsMore than 20% improvement in timely care delivery in home health pilotsPatient experience up approximately 5% YoYPatient access expanded by nearly 200,000 patient-facing hoursAI-based ambient listening capabilities available to 70% of employed providers, on track to exceed 90% by year-end
    		———at least $2.2 billion
    Optum Rx
    Performing to plan, leading industry shift towards transparency and fee-based services. New pharmacy care approach based on monthly per-member fees with full transparency.
    Client retention rates in the high 90sExpect to end 2026 with more than 95% of clients on 100% manufacturer rebate pass-through
    		————
    Optum Insight
    On multiyear path of reinvestment and innovation, bringing modern, intelligent technologies to the health system. AI-enabled approaches are gaining traction and driving impact for customers.
    Value Connect AI-driven insights platform: 17% reduction in pharmacy costs for early clientsDigital prior auth product processed 69,000 prior auths for external entities, saved 69,000 administrative hours
    		————

    Operational metrics

    27
    Adjusted EPS
    $6.3856.4% YoY
    Q2 FY26

    Compared to $4.08 in the prior year.

    Operating earnings
    $8 billion55% YoY
    Q2 FY26

    Year-over-year growth.

    Net favorable prior period medical development
    $860 million
    Q2 FY26

    Included in reported medical care ratio.

    Days claims payable
    47 daysup approximately 2.5 days YoY
    Q2 FY26

    Compared to a year ago.

    Operating cost ratio
    12.7%up from 12.3% YoY
    Q2 FY26

    As the company continues to focus on operating discipline while making targeted investments.

    Share repurchases deployed
    $4 billion
    YTD mid-July

    Through mid-July.

    Dividend per share (annualized)
    $9.28
    Q2 FY26

    Board increased dividend to this annualized amount.

    Debt-to-capital ratio
    41.2%down from 44.1% YoY, 170 bps sequential improvement
    Q2 FY26

    At the end of the quarter.

    UnitedHealthcare earnings weighting
    75%
    FY26

    Earnings continue to be weighted approximately 75% to the first half of the year.

    Optum Insight & Optum Rx earnings weighting
    55%
    FY26

    Expected to generate approximately 55% of their full year earnings during the back half of the year.

    Medicaid annualized rate impact
    around 6% to 7%lagging elevated medical trend
    2026

    Aggregate year-to-date rate actions through July 1, accounting for approximately 80% of annual revenue, were within expected forecast.

    Commercial medical cost trend
    modestly above 11%
    Q2 FY26

    Stubbornly high, rising above expectations.

    MA core utilization assumption (original 2026 bid)
    7.5%
    2026

    Original assumption for Medicare Advantage, based on elevated levels of core utilization in 2025.

    MA regulatory changes assumption (original 2026 bid)
    1.5%
    2026

    Original assumption for Medicare Advantage, related to fee schedule changes and calendar impacts.

    Optum Real digital prior auths processed (external entities)
    69,000
    YTD

    Processed for external entities to UHG.

    Optum Real digital prior auths processed (total)
    0.5 million
    YTD

    Total prior auths processed by the digital prior auth product.

    Optum Real digital prior auths administrative hours saved
    69,000
    YTD

    Saved by the digital prior auth product.

    OptumHealth hospitalization reduction
    approximately 10%
    since late last year

    Resulted from enhanced support for patients during key transitions of care.

    OptumHealth home health timely care delivery improvement
    more than 20%
    pilots

    Driven by home health initiatives to better support patients returning home.

    OptumHealth rural patient home visits
    approximately 2.5 million
    annually

    Conducted by OptumHealth, which reaches nearly 90% of U.S. counties.

    OptumHealth patient experience improvement
    approximately 5%
    YoY

    In care delivery sites.

    OptumHealth patient access expansion
    nearly 200,000
    YTD

    Expanded patient-facing hours.

    OptumHealth high-risk patient engagement increase
    about 6%
    YTD

    Increased patient engagement with high-risk population.

    OptumHealth ambient clinical documentation AI reduction in cognitive burnout
    90%
    YTD

    Reduction in cognitive burnout for clinicians using AI.

    Digital prior authorization first pass approval rate
    96%
    YTD

    Using AI for digital prior authorization.

    Optum Insight Value Connect pharmacy cost reduction
    17%
    YTD

    Early client results from the AI-driven insights platform.

    Investments in AI products and services
    1/3
    this year

    Approximately one-third of investments are going into commercializing internal AI use cases.

    Industry KPIs

    13
    MetricValueDetails
    Utilization trends7.5%%
    Same facility volumes—
    Stars rate environment—
    Medical loss care ratio86.7%%
    Client retention new winshigh 90s%
    Pharmacy scripts specialty—
    Payer mix supplemental payments—
    Membership covered lives by lineapproximately $1.1 millionmembers
    Segment revenue operating income—
    Prior year reserve development pdr$860 millionUSD
    Adjusted EPS EBITDA leverage guidance$19.50 to $20.00USD
    Prior authorization operational metrics30%%
    Medical cost trend vs pricing assumptionmodestly above 11%%

    Product announcements

    1
    ProductTypeDetails
    New pharmacy care approachlaunch

    Deals & partnerships

    1
    Alegeusacquisition

    Successfully closed the previously announced combination with Alegeus on July 2.

    Risks & headwinds

    4
    Elevated medical costs in Medicarethrough the first half of the year

    well above historical levels

    Mitigation: Benefit design, care management models, network curation.

    Pressured Medicaid marginsfor 2026

    negative 1% to negative 1.7% (expected 2026 margins), annualized 2026 rate impact will be in the zone of around 6% to 7% and still lagging elevated medical trend

    Mitigation: Partnering with states on appropriate rates, initiatives targeting elevated behavioral health cost trends, identifying and reducing fraud, waste and abuse.

    Stubbornly high commercial medical coststhrough the first half of the year, 2026

    modestly above 11% level we previously saw, 50 basis points or so of incremental trend in 2026 from IDR, totaling at least 100 basis points of total cost from IDR

    Mitigation: Improved administrative cost efficiency, AI-enhanced fraud waste and abuse efforts, diligent focus on medical cost affordability. Commercial margin recovery extended past 2027.

    Ineffective No Surprises Act IDR process2026, years past

    upwards of 40% of all claims that enter the IDR process are ineligible, roughly 60% of all arbitration cases are brought by 1 of just 5 entities, average payout from arbiters... is now 11x what Medicare would pay with some of those decisions ranging up to 30x

    Mitigation: Needs to be reformed.

    Q&A highlights

    6

    Inquire about Medicaid margin expectations for the year and the magnitude of commercial cost trend pressure, including the timeline for commercial margin recovery.

    Medicaid margins are expected to be within the previously communicated negative 1% to negative 1.7% range for 2026. Commercial trend is modestly above 11%, with 50 bps attributed to the IDR process. Commercial margin recovery is delayed past 2027 but is not a setback, aiming for 7% or greater.

    “I see '26 as a delay to that margin recovery trajectory, not a setback. So the sticky nature of the persistent and elevated trend is extending the time frame for full margin recovery past 2027, as we've previously discussed and you highlighted.”

    asked by Justin Lake · answered by Daniel Kueter

    2 min read7 chapters

    Detailed Narrative

    01

    Enterprise-Wide Modernization and AI Integration

    UnitedHealth Group is actively embracing AI to reimagine its operations, improve service interactions, reduce administrative burden, and support better decision-making across all businesses. This tech-forward view aims to simplify processes, increase consistency, and accelerate the redesign of healthcare experiences for consumers and providers. The company views AI as a core initiative and the operating infrastructure of the future, with significant opportunities for productivity gains and commercialization of internal tools.

    02

    UnitedHealthcare Performance and Strategic Adjustments

    UnitedHealthcare's overall Q2 performance exceeded expectations, driven by better results in Medicare Advantage due to benefit design, care management models, and network curation. While Medicare medical cost trends are below initial estimates, commercial costs remain stubbornly high, modestly above 11%, primarily due to the No Surprises Act IDR process and aggressive provider billing. The company is making reinvestments to build a stronger foundation for 2027 and beyond, focusing on modernizing essential healthcare experiences.

    03

    Optum's Integrated Value-Based Care Momentum

    All three Optum segments (OptumHealth, OptumRx, Optum Insight) are performing in line or ahead of plan. OptumHealth is seeing positive momentum from its integrated value-based care delivery model, with significant changes in operations leading to improved clinical care and operational experience. Initiatives like enhanced support during care transitions have reduced hospitalizations by approximately 10%, and home health initiatives have driven over 20% improvement in timely care delivery.

    04

    OptumRx's Transparency and Client Retention

    OptumRx continues to perform to plan, leading an industry shift towards transparency and fee-based services. The company announced a new pharmacy care approach based on monthly per-member fees with full PBM and GPO fee transparency, receiving positive client feedback. High client retention rates in the high 90s underscore the success of these initiatives, including the commitment to pass through 100% of manufacturer rebates by the end of 2027.

    05

    Optum Insight's AI-Enabled Solutions

    Optum Insight is on a multiyear path of reinvestment and innovation, bringing modern, intelligent technologies to the health system. AI-enabled approaches, such as AI-enabled coding and real-time payer/provider interfaces, are gaining traction, driving impact for customers. The Value Connect platform, an AI-driven insights tool, has shown early client results including a 17% reduction in pharmacy costs.

    06

    Commercial Market Challenges and IDR Process

    The No Surprises Act's Independent Dispute Resolution (IDR) process is identified as a significant driver of elevated commercial medical cost trends. Management notes that the IDR process is ineffective, with 40% of claims being ineligible and 60% of arbitration cases brought by just five entities. The average payout from arbiters is 11x what Medicare would pay, with some decisions up to 30x, indicating a need for reform.

    07

    Long-Term Growth and Mission Alignment

    The company reaffirms its commitment to a 13% to 16% long-term growth rate, driven by productivity gains and capital utilization, particularly leveraging technology. The focus extends beyond financial metrics to a broader mission of positively impacting all stakeholders in the health system, with a "restless and urgent" approach to continuous improvement and modernization.

    AI-generated summary of the company’s earnings call. Not investment advice.